Analysis of the differences between Lenvatinib (Lenvima) and Lenvatinib

LenvatinibandThe "lenvatinib" actually refers to the same active ingredient: lenvatinib. In the Chinese market, this drug is launched by Eisai in the form of "Lenvatinib Mesylate Capsules", with the trade name "LENVIMA"; in the International Pharmacopoeia and European and American drug regulatory agency documents, it is mostly identified by the generic name "Lenvatinib". In other words, "Lenvatinib" is the Chinese translation of the drug, "Lenvatinib" is its commercial name, and "Lenvatinib" is the International Nonproprietary Name (INN) named by the World Health Organization (WHO). All three represent the same molecular entity.

In terms of pharmaceutical classification, lenvatinib is an oral multi-target tyrosine kinase inhibitor (TKI). It blocks tumor angiogenesis and inhibits cancer cell proliferation and migration by inhibiting VEGFR1–3, FGFR1–4, PDGFRα, RET, KIT and other receptor signaling pathways. This mechanism determines its clinical value in a variety of solid tumors, especially in the treatment of liver cancer, kidney cancer, thyroid cancer, endometrial cancer and other diseases. It has become an important molecular targeted drug. Although the indications approved by regulatory agencies in many countries around the world are slightly different, the overall direction is the same, that is, for the treatment of advanced malignant tumors that cannot be surgically removed or are resistant to standard therapies.

In terms of the name system,the word "lenvatinib" reflects the standardized translation of the drug in the Chinese Pharmacopoeia and is used in doctors' prescriptions, medical insurance catalogs and drug regulatory registration documents. "Levima" is a brand name registered by Japan Eisai Company and is mainly used for pharmaceutical packaging, marketing and commercial sales. The product labels that patients see when purchasing in hospitals or pharmacies are often "Lenvima", but the active ingredient is also stated as "Lenvatinib Mesilate" in the instructions to ensure the recognizability of international standards. Due to the diversification of drug naming, there may be slight differences in labeling in different countries and regions, but the core active ingredients, pharmacological mechanisms and therapeutic effects are completely consistent.

Reference materials:https://www.lenvima.com/